ProShares Ultra Health Care ETF
RXL----
Weekly Recap | Pfizer -3.03%, most brokers rate it buy
Weekly Review·- Pfizer closed at 27.8 USD this week, recording a cumulative drop of 3.03% and underperforming the S&P 500 amid quiet trading and legal developments. - The company released multiple clinical pipeline data updates around the ESMO conference while facing ongoing patent lawsuits and a state-level lawsuit in Florida. - A total of 28 institutions provided a consensus buy rating with a target price of 28.91 USD, while the upcoming third-quarter financial report is scheduled for November 3, 2026.